Suppr超能文献

ST 段抬高型心肌梗死患者并发急性肾损伤的预测因素——不来梅 STEMI 注册研究结果。

Predictors of acute kidney injury in patients admitted with ST-elevation myocardial infarction - results from the Bremen STEMI-Registry.

机构信息

1 The Bremer Institut für Herz- und Kreislaufforschung am Klinikum Links der Weser, Bremen, Germany.

2 Nierenzentrum Bremen Sued, Germany.

出版信息

Eur Heart J Acute Cardiovasc Care. 2018 Dec;7(8):710-722. doi: 10.1177/2048872617708975. Epub 2017 Jun 15.

Abstract

BACKGROUND

: Deterioration of renal function after exposition to contrast media is a common problem in patients with myocardial infarction undergoing percutaneous coronary interventions. The aim of the present study was to assess the incidence of acute kidney injury in patients admitted with ST-elevation-myocardial infarction (STEMI) and its association with infarction severity, comorbidities and treatment modalities, including amount of contrast media applied.

METHODS

: All patients with STEMI from the metropolitan area of Bremen, Germany are treated at the Bremen Heart Centre and since 2006 documented in the Bremen STEMI-Registry. Acute kidney injury was graded from stage 0 to 3 following the Kidney-disease-improving-global outcomes criteria from 2012.

RESULTS

: Data from 3810 patients admitted with STEMI were included in this study. No acute kidney injury was observed in 3120 (82%) patients while acute kidney injury was detected in 690 (18%) patients: Stage 1: n=497 (13%), 2: n=66 (2%), 3: n=127 (3%). Acute kidney injury was associated with elevated 30-day (0: 3%, 1: 20%, 2: 46%, 3: 58%) and one-year mortality rates (0: 6%, 1: 26%, 2: 49%, 3: 66%). Higher acute kidney injury stages were associated with higher peak creatine kinase (in U/l±SEM): stage 0: 1748±33, 1: 2588±127, 2: 3684±395, 3: 3330±399, p (<0.01), lower mean systolic blood pressure at admission (in mmHG±SD): 0: 133±28, 1: 129±31; 2: 121±31, 3: 115±33 ( p<0.01) and higher Thrombolysis in Myocardial Infarction risk score for STEMI (scale 0-14±SD): 0: 2.71±2, 1: 4.08±2, 2: 4.98±2, 3: 5.05±2, ( p<0.01). However, no such association could be found between acute kidney injury stage and amount of contrast media applied (in ml±SD) 0: 138±57, 1: 139±61; 2: 140±76; 3: 145±80 ( p=0.5). Reduced initial glomerular filtration rate was associated with higher incidences of acute kidney injury while again no relation to amount of contrast media could be observed in subgroups ranked by initial glomerular filtration rate. A multivariate analysis confirmed these results: while left-heart-failure/cardiogenic shock (odds ratio (OR) 4.2, 95% confidence interval (CI) 3.3-5.5) as well as larger infarctions (peak creatine kinase >3000 U/l (OR 2.2, 95% CI 1.7-2.8)) were independently associated with a greater risk for acute kidney injury, amount of contrast media applied during angiography was not (150-250 ml, OR 0.95, 95% CI 0.8-1.2 ( p=0.7), >250 ml, OR 1.3, 95% CI 0.8-2.0 ( p=0.5)).

CONCLUSIONS

: Acute kidney injury, which was associated with elevated short- and long-term mortality rates, could be observed in 18% of patients admitted with STEMI. The present data suggest that severity and haemodynamic impairment due to STEMI rather than contrast-media-induced nephropathy is the key contributor for acute kidney injury in STEMI patients. The deleterious effect of the myocardial infarction itself on renal function can be explained through renal hypoperfusion, neurohormonal activation or other pathomechanisms that might have been underestimated in the past.

摘要

背景

心肌梗死患者经皮冠状动脉介入治疗后对比剂暴露导致肾功能恶化是一个常见问题。本研究旨在评估 ST 段抬高型心肌梗死(STEMI)患者中急性肾损伤的发生率及其与梗死严重程度、合并症和治疗方式的关系,包括应用的对比剂量。

方法

所有来自德国不来梅州的 STEMI 患者均在不来梅心脏中心接受治疗,并自 2006 年以来在不来梅 STEMI 注册中心进行了记录。根据 2012 年肾脏病改善全球结局(KDIGO)标准,将急性肾损伤分为 0 至 3 期。

结果

本研究纳入了 3810 例 STEMI 患者的数据。3120 例(82%)患者无急性肾损伤,690 例(18%)患者发生急性肾损伤:1 期:n=497(13%),2 期:n=66(2%),3 期:n=127(3%)。急性肾损伤与 30 天(0%:3%,1%:20%,2%:46%,3%:58%)和 1 年死亡率(0%:6%,1%:26%,2%:49%,3%:66%)升高相关。更高的急性肾损伤分期与更高的肌酸激酶峰值相关(单位:U/L±SEM):0 期:1748±33,1 期:2588±127,2 期:3684±395,3 期:3330±399,p(<0.01),入院时平均收缩压更低(单位:mmHg±SD):0 期:133±28,1 期:129±31;2 期:121±31,3 期:115±33(p<0.01)和更高的 STEMI 溶栓治疗风险评分(范围 0-14±SD):0 期:2.71±2,1 期:4.08±2,2 期:4.98±2,3 期:5.05±2,(p<0.01)。然而,在急性肾损伤分期和应用的对比剂量(单位:ml±SD)之间没有发现这样的关联:0 期:138±57,1 期:139±61;2 期:140±76;3 期:145±80(p=0.5)。初始肾小球滤过率降低与急性肾损伤发生率增加相关,而在按初始肾小球滤过率分组的亚组中,也没有观察到与对比剂量的关系。多变量分析证实了这些结果:左心衰竭/心源性休克(比值比(OR)4.2,95%置信区间(CI)3.3-5.5)以及更大的梗死(肌酸激酶峰值>3000 U/l(OR 2.2,95%CI 1.7-2.8))与急性肾损伤的风险增加独立相关,而造影期间应用的对比剂量则没有(150-250 ml,OR 0.95,95%CI 0.8-1.2(p=0.7),>250 ml,OR 1.3,95%CI 0.8-2.0(p=0.5))。

结论

在 STEMI 患者中,急性肾损伤的发生率为 18%,与短期和长期死亡率升高相关。本研究数据表明,STEMI 导致的严重程度和血液动力学损害,而不是对比剂诱导的肾病,是 STEMI 患者发生急性肾损伤的关键因素。过去可能低估了心肌梗死本身对肾功能的不良影响,这种影响可能是通过肾灌注不足、神经激素激活或其他病理机制来解释的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验